Inve US ▾
LNLNSR

LENSAR (LNSR) Q2 FY26 earnings call: the analyst Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 13, 2026

Source: earnings call transcript

Executive summary

LENSAR Q2 FY26 — Strong Revenue Growth and Record Adjusted EBITDA

LENSAR delivered a strong second quarter, demonstrating resilience and renewed momentum following the terminated merger. The company achieved robust top-line growth, driven by expanding recurring revenue and increased utilization of its ALLY system, leading to record adjusted EBITDA. Management is focused on strategic investments in commercial efforts to further expand its installed base and recurring revenue business, positioning for sustainable long-term growth despite anticipated Q3 seasonality.

Highlights

6
  • Total revenue grew 18% year-over-year to $16.5 million.

  • Recurring revenue increased 20% year-over-year to $13.7 million, representing 83% of total revenue.

  • Procedure revenue increased 23% year-over-year to $10.2 million, driven by 13% procedure volume growth to 58,682 procedures.

  • Adjusted EBITDA reached a record $3.6 million, reflecting improved profitability and operating leverage.

  • U.S. procedure market share expanded to 24.1% in Q2 FY26, up from 23.4% in Q1 FY26 and 21.4% in Q2 FY25.

  • Placed 10 ALLY systems, increasing the ALLY installed base to approximately 215 systems worldwide, with 13 ALLY systems in backlog.

Concerns

2
  • Operating expenses are expected to trend modestly higher, approaching historical levels, as the company increases investment in commercial efforts.

  • Historically, cataract surgery procedures are lowest in Q3 due due to extended holidays and summer vacations, which may impact near-term volume.

Risks & headwinds

Operating expenses expected to trend higher future quarters

modestly higher, approaching historical levels

Mitigation:Strategic investments in commercial efforts to support continued growth.

Seasonal slowdown in cataract surgery procedures third quarter

lowest of the year

What to watch in Q3 FY26

Operating Expense Trend

next several quarters
Current $7.6 million in Q2 FY26
Target modestly higher, approaching historical levels

Why it matters

Management plans to increase investment in commercial efforts, which will impact profitability and growth trajectory.

Looking ahead, we expect operating expenses to trend modestly higher, approaching historical levels as we begin to increase investment in commercial efforts to support continued growth.

Find out whether LNSR delivers this. Inve re-checks your case every morning.

Q&A highlights

Inquired about the geographic split (US/OUS) of the 13 ALLY systems in backlog and whether US systems are sales or placements, and how this impacts Q3/Q4 expectations.

Nicholas Curtis stated the backlog is a mix of OUS (primarily Q4 delivery due to holidays) and US systems (some sold, some placed). US installations are sometimes delayed by new facility construction.

“So it's -- with everything. It's a little bit of both. We have some backlog with POs, as I may have mentioned in the previous quarter conference call for primarily fourth quarter delivery OUS, given the sort of the holiday season and whatnot that I mentioned towards the end of my remarks. And then some backlog in the U.S. with a few sold and placed systems.”

asked by Frank Takkinen · answered by Nicholas Curtis

2 min read 6 chapters

Detailed narrative

Post-Merger Reset and Strategic Focus

LENSAR successfully reset its operations as an independent company after the Alcon merger termination in Q1 FY26. The company is now focused on rebuilding commercial momentum, expanding its installed base, increasing utilization, growing recurring revenue, and strengthening surgeon relationships. Q2 performance, including 18% total revenue growth and record adjusted EBITDA, reflects this renewed focus and the team's diligence in quickly resetting operations.

Recurring Revenue and Utilization Growth

A key highlight was the continued growth of recurring revenue, which increased 20% year-over-year to $13.7 million, comprising 83% of total revenue. This was driven by a 23% increase in procedure revenue to $10.2 million and a 13% rise in procedure volume to over 58,600 procedures.

LENSAR laser systems performed 31% more procedures than MarketScope's stated national average of installed systems, reinforcing the strength of the recurring revenue model.

Market Share Expansion and ALLY Adoption

LENSAR expanded its U.S. procedure market share to 24.1% in Q2 FY26, up from 23.4% in Q1 FY26 and 21.4% in Q2 FY25. The ALLY system continues to drive this growth, with 10 new placements in the quarter, bringing the ALLY installed base to approximately 215 systems worldwide.

ALLY now accounts for nearly half of the global installed base, reflecting the continued adoption and technology differentiation surgeons are seeing from the next-generation platform.

Financial Performance and Profitability

The company reported total revenue of $16.5 million, an 18% increase year-over-year. Gross margin was 59%, or 52% excluding a $1.1 million tariff refund. GAAP net income was $3.5 million, a significant improvement from a net loss of $1.8 million in Q2 FY25. Adjusted EBITDA reached a record $3.6 million, demonstrating operating leverage and disciplined cost management, despite lower noncash income from warrant liabilities.

Commercial Investments and Future Outlook

Management plans to gradually increase operating expenses to support commercial efforts and growth initiatives, reflecting confidence in long-term opportunities. While Q3 is historically a weaker quarter for cataract procedures due to extended holidays and summer vacations, the company remains focused on expanding its installed base and recurring revenue model to drive sustainable growth and shareholder value.

The current backlog of 13 ALLY systems provides visibility into future placements.

International Market Focus

LENSAR is expanding its presence in Europe, including attending ESCRS in Q3 FY26, to educate surgeons and increase interest in the ALLY system. This investment highlights Europe's potential as an increasingly important market for the company, as it seeks to rebuild and accelerate its OUS distributor relationships, which were impacted by the terminated merger.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.